All deliverables
Digital · HCPs or patients

Landing Page.
From hero + CTA to fully interactive, gated, audience-aware.

Audience
HCPs or patients
Format
Single responsive HTML page
Output
Deployable HTML/CSS/JS
Price from
£290

A standalone responsive HTML page built to convert.

Spectrum& landing pages are delivered as deployable HTML/CSS/JS — a single folder ready to upload to your web server or hosting platform. No framework, no CMS dependency, no external JavaScript unless specifically required. The page renders correctly on any device from 320px mobile to 1440px desktop.

Signal defines the strategic layer: what the page needs to achieve, how the audience gets there, what the CTA hierarchy should be, and where HCP-gating is required. Ink writes the copy. Pixel builds and tests the implementation. For regulated HCP content, Reg reviews against ABPI 2024 digital communications guidance.

Complex-tier landing pages support HCP/patient audience toggles, gated content behind professional verification, email capture with GDPR-compliant opt-in, and interactive data sections. Everything is built to standard HTML — no proprietary tools required on the client side.

The team behind it.

Core team shown. Complexity tier determines which additional specialists are activated.

Simple, Medium, or Complex — you choose the depth.

Simple Medium Complex
Scope Hero + CTA Full page (hero/benefit/evidence/CTA) Interactive · HCP/patient toggle · email capture
Team Sys, Ink, Signal, Pixel, Pace + Aria + Medi + Reg (regulated)
Price range ~£290 ~£550 ~£1,100
Best for Event registration, simple CTA page Product information hub, evidence landing page Full HCP resource centre, gated content, regulated digital detail aid

What it looks like.

Landing Page preview
spectrumand-demo.com/verixtol  ·  Desktop preview
Hartwell Pharmaceuticals · HCP Information
Verixtol® — New NEJM data
now available
Full VERIFY-1 52-week dataset, prescribing information, and ordering details for UK healthcare professionals.
Access the dataset →
This page is intended for UK healthcare professionals only. Prescribing information is available via the link above.
Landing page — Evidence section (Medium)
Section 2 of 4 — Evidence
The VERIFY-1 data. In full.
The primary endpoint of VERIFY-1 was PASI 90 response at week 16. This was achieved by 72% of patients in the verixtol 150mg group, compared to 4% in the placebo group (p<0.0001, n=312).
89%
PASI 75
78%
IGA 0/1
68%
DLQI 0/1
Landing page — HCP/patient toggle (Complex)
I am a healthcare professional
I am a patient or carer
Viewing: HCP version
Prescribing information
Verixtol® (verixtumab 150mg solution for injection). Indication: Moderate-to-severe plaque psoriasis in adults. Dosing: 150mg SC at weeks 0,1,2,3,4 then monthly. Contraindications: Hypersensitivity; active serious infection; active inflammatory bowel disease. Undesirable effects: Nasopharyngitis (14%), URTI (9%), ISR (6%). Full SmPC available at medicines.org.uk. Legal category: POM. MA number: EU/1/25/1847/001. Cost: £9,800 per patient per year (list price). Date of prescribing information: March 2026.
This information is intended for healthcare professionals only. If you are a patient, please toggle to the patient view above.

Full rendered examples will be available at launch.

ABPI 2024 Compliance

Promotional landing pages targeting HCPs are subject to ABPI 2024 digital communications guidance. Patient pages are reviewed for compliance with UK direct marketing regulations and MHRA advertising guidance.

Start your Landing Page.

Tell us about your brief. We'll assemble the right team and get started today.

Start a project →